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Abstract
Recent approaches of regenerative medicine can offer a therapeutic option for
patients undergoing acute kidney injury. In particular, mesenchymal stem cells
were shown to ameliorate renal function and recovery after acute damage. We
here evaluated the protective effect and localization of CD133+ renal progeni-
tors from the human inner medulla in a model of glycerol-induced acute
tubular damage and we compared the results with those obtained with bone
marrow-derived mesenchymal stem cells. We found that CD133+ progenitor
cells promoted the recovery of renal function, preventing tubular cell necrosis
and stimulating resident cell proliferation and survival, similar to mesenchy-
mal stem cells. In addition, by optical imaging analysis, CD133+ progenitor
cells accumulated within the renal tissue, and a reduced entrapment in lung,
spleen, and liver was observed. Mesenchymal stem cells were detectable at
similar levels in the renal tissue, but a higher signal was present in extrarenal
organs. Both cell types produced several cytokines/growth factors, suggesting
that a combination of different mediators is involved in their biological
action. These results indicate that human CD133+ progenitor cells are reno-
tropic and able to improve renal regeneration in acute kidney injury.
Introduction
The intrinsic ability of tissue repair and regeneration nec-
essary to regain functionality after ischemic, toxic, or
inflammatory insults is limited in the mammalian kidney.
Acute kidney injury (AKI) remains a major cause of
in-hospital morbidity and mortality despite supply of
supportive care, and possibly leads to chronic renal dys-
function (Goldstein et al. 2013). Recently, stem cell-based
therapy appeared as a new strategy to support renal
repair, being bone marrow-derived mesenchymal stem
cells (MSCs) the most studied cell type and the most
advanced in clinical development (T€ogel et al. 2005).
Injected bone marrow-derived MSCs are known to dis-
play a renoprotective effect in models of acute kidney
injury mainly through paracrine mechanisms (Bi et al.
2007).
In parallel, different experimental studies showed the
potential application of adult renal progenitors derived
both from mouse or human renal tissue for the treatment
of AKI (Bussolati et al. 2005; Dekel et al. 2006; Sagrinati
et al. 2006; Kinomura et al. 2008; Langworthy et al. 2009;
Ronconi et al. 2009; Lee et al. 2010). In humans, CD133+
cells, characterized by features of nondifferentiated renal
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mesenchymal progenitors, were mainly identified in the
Bowman capsule of glomeruli and in the proximal tubules
(Bussolati et al. 2005; Sagrinati et al. 2006; Sallustio et al.
2010). These cortical CD133+ progenitor cells have been
injected in murine models of glomerular toxicity and
tubular necrosis (Bussolati et al. 2005; Sagrinati et al.
2006; Ronconi et al. 2009). In all experiments, injected
CD133+ progenitors were detected into the renal injured
tissue and were found to ameliorate renal function
(Bussolati et al. 2005; Sagrinati et al. 2006; Ronconi et al.
2009). However, the localization of renal CD133+ cells in
living animals and their biodistribution in the different
organs has not yet been evaluated.
CD133+ progenitor cells were also detected in the inner
medullary papilla region, being localized in the Henle’s
loop and in the S3 limb segments (Ward et al. 2011;
Bussolati et al. 2012). CD133+ cells isolated from the
renal medulla were shown to possess higher differentiative
ability and stemness markers with respect to those in
proximal tubules, possibly due to the maintenance of
stem features in the hypoxic environment of the inner
medulla (Bussolati et al. 2012). Therefore, it could be of
interest to evaluate the in vivo effect and localization of
the medullary CD133+ progenitor cells in models of AKI.
The present study was designed to investigate the effect
of labelled CD133+ progenitor cells isolated from the
human renal medulla after intravenous injection in mice
with glycerol-induced AKI. In addition, we report for the
first time their biodistribution using optical imaging. The
effect of renal progenitors was compared with that of
bone marrow-derived MSCs.
Materials and Methods
Cells and labeling procedure
Renal CD133+ progenitor cells were obtained from the
normal portion of the papillary region of the inner
medulla obtained from surgically removed kidneys
(Bussolati et al. 2012), after approval of the Ethical Com-
mittee for the use of human tissue of the Department of
Medical Sciences of the University of Torino. Briefly, tis-
sue samples of approximately 3–5 mm3 were obtained at
the papillary region of a renal pyramid. Tissue was rinsed
with Hank’s Balanced Salt Solution (Sigma, St. Louis,
MO) and, after cutting, digested in 0.1% Collagenase type
I (Sigma) for 45 min at 37°C. Tissue was subsequently
forced through a graded series of meshes to separate the
cell components from stroma and aggregates. The filtrate
was pelleted by centrifugation. CD133+ cells were isolated
by magnetic cell sorting, using the MACS system (Milte-
nyi Biotec, Bergisch Gladbach, Germany), and cells resus-
pended in expansion medium (EBM medium plus
supplement kit; Lonza, Basel, Switzerland) without serum
addition at a density of 1 9 105 viable cells per cm2. Cell
lines, obtained from different renal specimens were used
between passage 2 and 5. Bone marrow-derived MSCs
were obtained from Lonza, cultured and characterized as
previously described (Herrera et al. 2007; Bruno et al.
2009). Briefly, the MSCs were cultured in the presence of
Mesenchymal Stem Cells Basal Medium (MSCBM, Lon-
za). All cell preparations at different passages of culture
expressed the typical MSC markers: CD105, CD73, CD44,
CD90, CD166, and CD146 and not hematopoietic mark-
ers like CD45, CD14, and CD34, evaluated by cytofluori-
metric assay (Table 1). The adipogenic, osteogenic, and
chondrogenic differentiation ability of MSCs was deter-
mined as previously described (Herrera et al. 2007).
Cells were labeled with DiD (Ex: 640 nm; Em: 700 nm)
(Molecular Probes, Life Technology, NY) solution with-
out serum for 20 min at 37°C (Garrovo et al. 2013; Her-
rera et al. 2013). Cells were then washed in complete
medium by centrifugation and cultivated for 24 h before
injection in vivo. Cells were counted and viability tested
by the trypan blue exclusion assay (Sigma).
Optical imaging
All the studies were performed with IVIS 200 small ani-
mal imaging system (PerkinElmer, Waltham, MA) using
excitation filter at 640 nm and emission filter at 700 nm.
Identical illumination settings, such as exposure time
Table 1. Phenotypic characteristics of CD133+ cells and MSCs.
Cell preparations CD133 CD24 CD73 CD105 CD44 CD73 CD29 Vimentin Pax2
CD133+ cells 97.5 84.9 95.5 6.4 96.2 71.3 81.9 >95 >95
MSCs 0 0 97.3 73.0 91.3 89.3 88.1 >95 0
The expression of the renal progenitor markers CD133 and Pax2 and of the mesenchymal markers CD73, CD105, CD44, CD29, and vimentin
by the cell isolates used in the study was evaluated by cytofluorimetric analysis or immunofluorescence staining, as described (Bruno et al.
2009; Goldstein et al. 2013). Cells were tested between the second and the third culture passage. Data are expressed as % positive cells and
are mean of four different cells lines for CD133+ cells and of three different cell lines for MSCs.
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(2 sec), binning factor (4), f/stop (2), and field of views
(Herrera et al. 2013), were used for acquiring all images,
and fluorescence emission was normalized to photons per
second per centimeter squared per steradian (p/sec/cm2/sr).
The color image represents the spatial distribution of
fluorescence within the animal overlaid on black and
white photographs of the mice, collected at the same
time. Images were acquired whole body and on organs
collected 48 h after cell injection. To control for the back-
ground photon emission, the obtained data were sub-
jected to average background subtraction, using data
captured with an excitation of 535 nm. Images were
acquired and analyzed using Living Image 4.0 software
(PerkinElmer) (Herrera et al. 2013). The fluorescence
(p/sec/cm2/sr) was quantified in region of interest (ROI)
draw freehand. Data were expressed as average radi-
ance  SD.
Glycerol-induced model of AKI
Animal studies were conducted in accordance with the
National Institutes of Health Guide for the Care and Use
of Laboratory Animals. The protocol was approved by the
Committee of Bioethics of the University of Torino (Per-
mit Number: 1.3.10). Mice were kept in our institutional
animal facility under well-controlled conditions of
temperature, humidity with access to food and water ad
libitum. AKI was induced in SCID mice (Charles River
Laboratories, Lyon, France) by i.m. injection of 7.5 mL/kg
glycerol (Sigma). Mice received 5 9 105 CD133+ progeni-
tors or MSCs in 150 lL PBS or an equal volume of PBS
as control (n = 6 mice/group for each experimental
point) 24 h after the glycerol injection. Mice were sacri-
ficed at different times after cell or vehicle administra-
tions, and kidneys and samples for blood urea nitrogen
(BUN) and creatinine determination were collected. The
animals were monitored for activity and physical condi-
tions every day. For biodistribution experiments, male
CD1 nude mice were used (Charles River Laboratories).
Mice were fed for 1 week with a special diet (AIN 79,
Mucedola, Settimo Milanese, Italy) to reduce tissue auto-
fluorescence. Twenty-four hours after AKI damage, mice
were treated with labeled CD133+ progenitors (n = 8) or
MSCs (n = 6) or PBS (n = 8) and sacrificed 48 h after.
Renal function
Blood samples for measurement of BUN and plasma cre-
atinine were collected 0, 1, 3, 5, and 8 days after glycerol
treatment. Serum creatinine was measured using a colori-
metric microplate assay based on the Jaffe reaction
(Quantichrom Creatinine Assay, BioAssay Systems,
Hayward, CA). BUN was measured by direct quantifica-
tion of serum urea with a colorimetric assay kit according
to the instruction protocol (Quantichrom Urea Assay,
BioAssay Systems).
Morphological studies
For renal histology, 5 lm-thick paraffin kidney sections
were routinely stained with hematoxylin and eosin. Lumi-
nal hyaline casts and cell lose (denudation of tubular base-
ment membrane) were assessed in nonoverlapping fields
(up to 10 for each section) using a 409 objective (high-
power field, HPF). Number of casts and tubular profiles
showing necrosis were recorded in a single-blind fashion
(Bruno et al. 2009). Immunohistochemistry for the detec-
tion of proliferation of tubular cells was performed as pre-
viously described (Bruno et al. 2009). Briefly, kidney
sections were subjected to antigen retrieval, and slides were
blocked and labelled with 1:400 of monoclonal anti-PCNA
(Santa Cruz Biotechnology, Santa Cruz, CA). Immunoper-
oxidase staining was performed using 1:300 dilution of
anti-mouse HRP (Pierce, Rockford, IL). Scoring for
PCNA-positive cells was carried out by counting the num-
ber of positive nuclei per field in 10 randomly chosen sec-
tions of kidney cortex using 409 magnification.
Apoptosis was performed by TUNEL assay (Millipore,
Vimodrone, MI) on slices of kidneys recovered after 48 h
post cell injection (day 3), following the manufacturer’s
instruction. The number of apoptotic cells per field in 10
randomly chosen sections, using 2009 magnification, was
counted and expressed as mean  SD.
Confocal microscopy analysis was performed on frozen
sections for the detection of HLA-class I, of Ki67 prolifer-
ation marker, and of pan cytokeratin. Sections were
labelled with mouse anti-HLA and rabbit polyclonal anti-
Ki67 antibodies (both from Abcam, Cambridge Science
Park, UK) or with rabbit anti-HLA (Santa Cruz) and
mouse anti-pan cytokeratin (Biolegend, San Diego, CA)
or rat anti-CD31 (Abcam). Alexa Fluor anti-rabbit or
anti-mouse or anti-rat antibodies (Molecular Probes, Lei-
den, the Netherlands) were used as secondary antibodies.
Confocal microscopy analysis was performed using a Zeiss
LSM 5 Pascal Model Confocal Microscope (Carl Zeiss
International, Germany). Hoechst 33258 dye (Sigma) was
added for nuclear staining. HLA-positive cells were
counted in 10 randomly chosen sections, using 4009
magnification, and expressed as mean  SD.
Cytokine assay
To measure the cytokines produced by CD133+ cells and
by MSCs, we performed a multiplex cytokine array based
on fluorescently dyed microspheres (Bio-Plex, Biorad,
Hercules, CA). CD133+ cells and MSCs were cultured to
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a confluence of 90%. Cells were then cultured for 12 h in
DMEM (Lonza) with 0.5% albumin (Sigma) and superna-
tant (conditioned medium) collected and frozen at
20°C after centrifugation (1200 rpm, 4°C, 5 min) to
remove cellular debris. The cytokine assay was performed
for three different isolated cells of CD133+ cells and
MSCs.
Statistical analysis
Results are generally expressed as mean  SD. Statistical
analysis was performed by ANOVA with Dunnett’s multi-
comparison test. A P-value of <0.05 was considered sig-
nificant.
Results
Effect of CD133+ cells on the recovery of
glycerol-induced AKI and comparison with
MSCs
CD133+ cells isolated from the human renal inner
medulla were previously described to display progenitor
phenotype and properties (Bussolati et al. 2012, 2013).
A
C
D E
B
Figure 1. Effect of CD133+ cells or MSCs on renal function and morphology in AKI mice. Changes in renal function were measured by (A)
BUN and (B) creatinine. Glycerol injection resulted in elevated BUN and creatinine levels with a peak at day 1. In animals injected with CD133+
cells at day 1 (arrow), BUN and creatinine levels showed a significant amelioration as soon as 48 h after injection (day 3) that was maintained
at day 5. The effect of CD133+ cells was compared to that of MSCs injected at day 1. Data are mean  SD of six SCID mice/group/
experimental point. (C) Representative micrographs of renal tissue from AKI mice on day 3 after damage showing tubular necrosis, tubular
protein casts and loss of brush border. Kidneys from mice treated with CD133+ cells or MSCs showed signs of recovery of tissue injury. Original
magnification 2009. Count of tubular (D) necrosis and (E) tubular casts at day 3 and 5 after glycerol injection. Data are mean  SD of the
count of 10 fields/section in two sections/mouse. n = 6 mice for each experimental point were evaluated. ANOVA with Dunnett’s
multicomparison test was performed: *P < 0.05 stem cell treated versus PBS; §P < 0.001 stem cell treated versus PBS.
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CD133+ cells expressed several markers in common with
MSCs (CD73, CD29, CD44, and vimentin, but not
CD105) and, at variance of MSCs, the renal embryonic
marker PAX2, indicating their renal origin (Table 1). To
investigate the therapeutic effect of CD133+ cells derived
from the human inner medulla, experimental AKI was
induced in SCID mice by glycerol injection, as described
before (Bussolati et al. 2005; Bruno et al. 2009). Intra-
muscular injection of glycerol causes rhabdomyolyses of
the muscular tissue, thereby releasing large quantities of
enzymes, myoglobin, and iron and causing renal tubular
injury. After the glycerol injection, serum creatinine and
BUN levels increased as soon as after 24 h, and remained
elevated over the course of 5 days to normalize thereafter.
One day after the induction of AKI, mice received
5 9 105 CD133+ cells or MSCs intravenously via the tail
vein. Control animals received only PBS. Mice injected
with CD133+ cells exhibited a rapid amelioration of the
renal function, as valuated by BUN and creatinine levels
(Fig. 1A and B). In particular, a significant reduction in
BUN and creatinine was observed at day 3 (48 h after
treatment) and 5 with respect to that in animals treated
with PBS alone. We next compared the effect of CD133+
cells with that of MSCs. As expected, MSCs rapidly
protected against the development of AKI. The levels of
BUN were lower in animals treated with MSCs with
respect to CD133+ cells, whereas no difference was
observed in creatinine levels (Fig. 1A and B).
CD133+ cells and MSCs inhibited tubular
necrosis and enhanced cell proliferation
On day 3 after injury, the histological evaluation of the
renal tissue of glycerol-injected mice showed diffuse epi-
thelial damage characterized by necrosis and vacuolization
of tubular epithelial cells. In addition, proximal tubular
cells showed loss of brush border and intratubular protein
casts (Fig. 1C). Animals treated with CD133+ cells or
MSCs exhibited reduced tissue damage compared to PBS-
treated control animals as soon as at day 3 after glycerol
injection (48 h after stem cell injection) (Fig. 1C). As
assessed by morphometric evaluation of injury, stem
A B
C D
Figure 2. Tubular proliferation and apoptosis in AKI mice treated with CD133+ cells or MSCs. (A) Representative micrographs of TUNEL-
positive cells in AKI mice treated with PBS or stem cells. A significant reduction in apoptotic cells was observed in mice injected with CD133+
cells or MSCs. Original magnification 2009. (B) Graphs illustrating the quantification of TUNEL-positive cells at day 3 in AKI mice treated with
CD133+ cells or MSCs or injected with PBS. Data are expressed as mean  SD of the count of 10 fields/section in two sections/mouse. n = 6
mice for each experimental point were evaluated. ANOVA with Dunnett’s multicomparison test was performed: §P < 0.001 stem cells versus
PBS. (C) Representative micrographs showing PCNA-positive cells in kidney tissue from AKI mice injected with PBS or with CD133+ cells or
MSCs at day 3 after damage. Original magnification 2009. (D) Graphs illustrating the quantification of PCNA-positive cells at day 3 in AKI mice
treated with CD133+ cells or MSCs or injected with PBS as control. Data are expressed as mean  SD of the count of 10 fields/section in two
sections/mouse. n = 6 mice for each experimental point were evaluated. ANOVA with Dunnett’s multicomparison test was performed:
*P < 0.05 stem cells versus PBS.
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cell-injected animals had a significantly lower number of
cast containing tubules and a lower number of necrotic
tubules compared to PBS-treated animals with AKI
(Fig. 1D and E). Moreover, mice that received CD133+ or
MSCs showed a significant reduction in apoptotic tubular
cells compared with animals treated with PBS, as detected
by TUNEL assay (Fig. 2A and B). No significant differ-
ence was observed between animals treated with CD133+
cells or MSCs.
We next evaluated the proliferation of proximal tubular
cells in animals with AKI as a parameter of renal regener-
ative response. Treatment with CD133+ cells as well as
with MSCs induced a significantly higher proliferation of
tubular cells with respect to PBS-treated controls at day 3
after injury (Fig. 2C and D).
Intravenously-injected CD133+ cells and
MSCs localized in the kidney of AKI mice
The cell accumulation within the kidney was assessed by
IVIS using CD133+ cells or MSCs labelled with DiD dye.
A linear relation between cell number and fluorescence
intensity was observed on labeled cells in vitro and a
small number of cells, as low as 5 9 103, was detectable.
Equal number of CD133+ cells or MSCs generated com-
parable signals (Fig. 3A). Localization of the labeled cells
was observed in whole body images and in ex vivo iso-
lated organs at 48 h after the injection (day 3) (Figs. 3
and 4). As shown in Figure 3B and C, 48 h after intrave-
nous injection CD133+ cells were detectable in the kidney
with AKI damage. The fluorescence signal was higher
than that of PBS-treated animals and clearly detectable in
the kidney region although lower than that obtained with
labeled MSCs (Fig. 3B and C).
The analysis of isolated organs revealed a high localiza-
tion of CD133+ cells within the kidney similar to that of
MSCs (Fig. 4A and B). At variance, the localization
within spleen and liver was significantly higher for MSCs
than for CD133+ cells (Fig. 4C). Accumulation in lung
was similar for the two cell types (Fig. 4C).
Immunofluorescence staining performed using human
HLA Class I confirmed the engraftment of CD133+ cells
and MSCs cells within the renal tissue after 48 h (Fig. 5).
Cells were mainly present in renal interstitial tissue, but
some CD133+ cells or MSCs were also detectable within
glomeruli or tubular structures. No difference in cell
number (12.9  7.2 CD133+ cells; 13.4  6.2 MSCs) or
localization was detectable between the two stem cell
A
C
B
Figure 3. Localization of labeled stem cells in vivo by IVIS. (A) Representative fluorescence images of increasing number of DiD-labeled stem
cells (from 2.5 9 103 to 500 9 103) in an equal volume of 100 lL PBS evaluated in vitro. (B) Representative fluorescence images of mice with
AKI injected with DiD-labeled stem cells or PBS evaluated at day 3 after damage. (C) Quantification of fluorescence intensity of the kidney
region, calculated in ROI, expressed as the mean of average radiance  SD of mice injected with labelled CD133+ cells or MSCs or PBS. Eight
nude mice injected with PBS or CD133+ cells and six with MSCs were evaluated. ANOVA with Dunnett’s multicomparison test was performed:
*P < 0.05 stem cells versus PBS.
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sources. Colocalization studies with cytokeratin and CD31
showed absence of differentiation into epithelial or endo-
thelial cells at this time point. In addition, double staining
with Ki67 and HLA Class I showed that that the majority
of human cells were not in a proliferative phase (Fig. 5B).
Comparison of grow factors and cytokines
produced by cultured CD133+ cells and MSCs
To investigate the possible mechanisms of repair induced
by CD133+ cells and MSCs, we investigated the secretion
of cytokines involved in tissue repair by a multiplex cyto-
kine assay (Fig. 6). Both cell types released high levels of
vascular endothelial growth factor. The main difference in
cytokine/growth factors produced by CD133+ cells and
MSCs was a preferential release of platelet-derived growth
factor, fibroblast growth factor, leukemia inhibitory fac-
tor, and tumor necrosis factor a by CD133+ cells with
respect to MSCs. In addition, IL-15, a kidney-specific fac-
tors involved in renal differentiation (Giron-Michel et al.
2013), was selectively released by CD133+ cells. At vari-
ance, MSCs showed a selective release of hepatocyte
growth factor, known to be involved in epithelial cell
regeneration (Matsumoto and Nakamura 2001).
Discussion
In the present study, we investigated the potential of renal
progenitor cell therapy in murine experimental AKI. We
demonstrated that CD133+ progenitor cells isolated from
the human renal inner medulla accelerate the recovery of
AKI, similar to MSCs, prevented tubular cell necrosis and
promoted cell proliferation. In addition, CD133+ progeni-
tor cells were detectable by optical imaging within the
renal tissue, with low entrapment in extrarenal organs.
Several experimental evidences indicate that administra-
tion of cells with stem/progenitor properties is effective in
preventing renal damage and promoting its recovery after
an ischemic or toxic insult. In this setting, MSCs from
bone marrow or from fat and neonatal birth-associated
tissues (umbilical cord, placenta, and amniotic fluid) were
proved to be successful (Aggarwal et al. 2013; Casiraghi
et al. 2013).
A possible additional benefit in the exploitation of the
regenerative properties of MSCs may derive from the use
of tissue-specific cells. Indeed, the gene expression profile
comparative analysis of murine MSCs derived from kid-
ney and bone marrow showed that renal MSCs express a
selected pattern of genes possibly related to a memory of
A
C
B
Figure 4. Ex vivo localization of labeled stem cells. (A) Representative fluorescence images of dissected organs of AKI mice sacrificed 48 h after
injection of DiD-labeled CD133+ cells or MSCs or PBS (day 3). (B) Quantification of the fluorescence intensity of kidneys, calculated in ROI,
expressed as the mean of average radiance  SD. Kidneys from eight nude mice injected with PBS or CD133+ cells and from six nude mice
injected MSCs were evaluated. ANOVA with Dunnett’s multicomparison test was performed: *P < 0.05 stem cells versus PBS. (C) Quantification
of fluorescence intensity of organs (lung, liver, spleen), calculated in ROI, expressed as the mean of average radiance  SD of organs from AKI
mice injected with labelled CD133+ or MSCs or PBS.
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tissue origin (Pelekanos et al. 2012). This suggests that
renal MSCs exhibit organ-specific characteristics that
could provide an advantage with respect to MSCs from
unrelated organs. Cells with mesenchymal features and
progenitor properties have been detected by mean of
CD133 expression within different segments of the neph-
ron (Bussolati et al. 2005, 2012; Sagrinati et al. 2006;
Sallustio et al. 2010; Smeets et al. 2013). The physiologi-
cal involvement of resident CD133+ progenitors in tissue
regeneration after injury has been indicated by studies
showing the increase and proliferation of these cells in
renal transplanted kidneys undergoing ischemic damage
and in biopsies of AKI patients (Loverre et al. 2008; Sme-
ets et al. 2013). In addition, administration of CD133+
cells from tubules was reported to promote repair in AKI
models, mainly by engraftment within murine tubules
(Bussolati et al. 2005). Recently, a population of CD133+
cells has been detected in the renal medulla (Ward et al.
2011; Bussolati et al. 2012). We here show that CD133+
cells isolated from the human inner medulla and
expanded in vitro promoted the recovery of renal func-
tion in a glycerol model of AKI. Moreover, CD133+ cells
ameliorated the morphological features of the injured kid-
neys, reducing tubular necrosis and casts and promoting
tubular cell proliferation and survival.
The effects observed after CD133+ cell infusion in
terms of renal function were comparable to those of bone
marrow-derived MSCs, as reported previously (Herrera
et al. 2004, 2007; Imberti et al. 2007; Morigi et al. 2008).
At variance, we observed a clearly different biodistribu-
tion of the injected cells. Cells have been tracked using
fluorescence methods with NIR dyes, such as the DiD
dye, that provide efficient cell labeling without toxicity
with a stable and strong signal. The use of small-molecule
fluorophores and, in particular, NIR molecules is a pow-
erful tool to track stem cells for noninvasive visualization,
giving the possibility to follow and to localize labeled cells
in living whole-body animal. These dyes were employed
for in vivo cell, antibody, and extracellular vesicle detec-
tion (Zou et al. 2009; Boddington et al. 2011; Hood et al.
2011). Using optical imaging, previous experiments
showed the possibility to localize and compare the distri-
bution of MSCs in the kidney and other organs of AKI
animals after intravenous or intra-arterial injection (T€ogel
et al. 2008). We here confirmed using optical imaging
that after injection in the tail vein, MSCs distributed in
several organs, including kidney, lung, liver, and spleen.
At variance CD133+ cells showed a high renal localization,
but a reduced entrapment in lung, liver, and spleen.
It has been reported that paracrine factors released
from MSCs localized in distant sites could be sufficient
for their beneficial effects (Zhuo et al. 2013). In addition,
as during AKI other organs such as the lung can be
injured (Ahuja et al. 2012), the nonspecific homing of the
injected cells might also contribute to systemic tissue
repair. Nevertheless, the localization of the administered
cells in the kidney might be more effective to obtain the
desired therapeutic properties even when paracrine mech-
anisms are involved. In fact, within injured tissues, cells
are exposed to an advantageous inflammatory environ-
ment that may influence their behavior leading to a bidi-
rectional effect, from cells to the tissue and backward
(Del Tatto et al. 2011).
A
B
Figure 5. Detection of CD133+ cells or MSCs within the kidney of
AKI mice. (A) Representative confocal micrographs showing the
presence of CD133+ cells or MSCs within the kidney of mice with
AKI at day 3 after damage as evaluated by HLA Class I (red).
Localization of cytokeratin or CD31 positive cells is shown in green.
(B) Representative confocal micrographs showing the presence of
CD133+ cells or MSCs and of proliferating positive cells within the
kidney of mice with AKI at day 3, as evaluated by HLA Class I (red)
and Ki67 (green), respectively. Nuclei were counterstained with
DAPI (blue). Original magnification 4009.
2014 | Vol. 2 | Iss. 5 | e12009
Page 8
ª 2014 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
the American Physiological Society and The Physiological Society.
Localization of CD133+ Progenitor Cells in AKI C. Grange et al.
Previous studies showed the integration of CD133+
cells isolated from cortex within murine renal structures
as well as their proliferation (Bussolati et al. 2005; Ange-
lotti et al. 2012). We here found that CD133+ cells,
observed at an early time (48 h after their injection), were
mainly localized in the interstitium and few cells were
also detectable within renal tubular or glomerular struc-
tures. However, we only found a limited proliferation of
CD133+ cells from the inner medulla, possibly indicating
the involvement of paracrine mechanisms, as already
described for MSCs (Imberti et al. 2007; Bruno et al.
2009; Gatti et al. 2011). This is also suggested by the lack
of acquirement of epithelial or endothelial markers.
Although further studies are required to analyze the pos-
sible integration of CD133+ cells from inner medulla in
the murine kidney and their differentiation at later time,
these results may suggest that these cells display differen-
tial properties with respect to those from cortex, as previ-
ously described (Bussolati et al. 2012). Indeed, CD133+
cells from the inner medulla were shown in vitro to be
responsible for erythropoietin production (Bussolati et al.
2013). In the context of AKI, erythropoietin may play tis-
sue-specific roles unrelated to erythropoiesis such as mod-
ulation of angiogenesis and cell survival (Bahlmann and
Fliser 2009; Wenger and Hoogewijs 2010). Moreover, sev-
eral other factors released by CD133+ cells are considered
of great importance in the modulation of renal regenera-
tion. In particular, IL-15 is a survival factor for tubular
cells, involved in the maintenance of the renal epithelial
phenotype (Giron-Michel et al. 2013).
In conclusion, our results suggest that human isolated
CD133+ renal progenitors could be suitable for cell
therapy in acute tubular damage. In addition, these cells
showed characteristics that might be related to their renal
origin, such as their high renal localization and the pro-
duction of renoprotective factors that could be exploited
for renal regeneration. The possible clinical application of
CD133+, both from cortex and medulla, might be limited
by the availability of the organ source in comparison to
multiple sources available for MSCs. However, the knowl-
edge of the function of human CD133+ cells could lead
to new pharmacological approaches targeting renal pro-
genitors.
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